Firestone Karen
Known title: DirectorCIK: 0001969821
Firestone Karen's purchase track record
How the stock did after each of Firestone Karen's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 5 since March 16, 2023
Stock higher 6 months later
50%
3 months: 60%
Median 6-month return
-2.9%
3 months: +11.0%
Beat the S&P 500
50%
median -13.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/21/2026 | AMLX | $51K | +184.9% | pending | — |
| 12/23/2025 | AMLX | $101K | +11.0% | +33.0% | +6.6% |
| 9/5/2024 | AMLX | $107K | +125.9% | +64.1% | +4.3% |
| 12/15/2023 | AMLX | $60K | -77.2% | -88.5% | +15.1% |
| 3/16/2023 | AMLX | $32K | -22.8% | -38.9% | +13.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMLX | ▲ Buy | Option Exercise | 25,000 | $44K | 8/31/2026 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 25,000 | $126K | 8/31/2026 | View on chart |
| AMLX | ▲ Buy | Open Market | 3,800 | $51K | 5/21/2026 | View on chart |
| AMLX | ▲ Buy | Open Market | 8,100 | $101K | 12/23/2025 | View on chart |
| AMLX | ▲ Buy | Open Market | 50,000 | $107K | 9/5/2024 | View on chart |
| AMLX | ▲ Buy | Open Market | 4,000 | $60K | 12/15/2023 | View on chart |
| AMLX | ▲ Buy | Open Market | 1,000 | $32K | 3/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.